Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United States of America et al v. Bristol-Myers Squibb Co., et al
Case Number:
1:11-cv-00029
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 30, 2015
Bristol-Myers Faces Retaliation Suit After FCA Claims Axed
An Ohio federal judge on Friday dismissed False Claims Act allegations that Bristol-Myers Squibb Co. and Otsuka America Pharmaceutical Inc. defrauded the government and used kickbacks to promote off-label sales of antipsychotic drug Abilify, but left intact whistleblowers' retaliation claims against BMS.
-
October 09, 2014
BMS, Otsuka Say Abilify FCA Claims Don't Stick
Bristol-Myers Squibb Co. and Otsuka America Pharmaceutical Inc. asked an Ohio federal court Wednesday to toss a whistleblower False Claims Act suit alleging the companies defrauded the government and offered kickbacks to promote off-label uses of the antipsychotic Abilify, arguing the suit fails to detail any false claims.